Membrane particles from mesenchymal stromal cells reduce the expression of fibrotic markers on pulmonary cells

PLoS One. 2021 Mar 17;16(3):e0248415. doi: 10.1371/journal.pone.0248415. eCollection 2021.

Abstract

Background: Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease with limited treatment options in which the telomere shortening is a strong predictive factor of poor prognosis. Mesenchymal stromal cells (MSC) administration is probed in several experimental induced lung pathologies; however, MSC might stimulate fibrotic processes. A therapy that avoids MSC side effects of transformation would be an alternative to the use of living cells. Membranes particles (MP) are nanovesicles artificially generated from the membranes of MSC containing active enzymes involved in ECM regeneration. We aimed to investigate the anti-fibrotic role of MP derived from MSC in an in vitro model of pulmonary fibrosis.

Methods: Epithelial cells (A549) and lung fibroblasts, from IPF patients with different telomere length, were co-cultured with MP and TGF-β for 48h and gene expression of major pro-fibrotic markers were analyzed.

Results: About 90% of both types of cells effectively took up MP without cytotoxic effects. MP decreased the expression of profibrotic proteins such as Col1A1, Fibronectin and PAI-1, in A549 cells. In fibroblasts culture, there was a different response in the inhibitory effect of MP on some pro-fibrotic markers when comparing fibroblast from normal telomere length patients (FN) versus short telomere length (FS), but both types showed an inhibition of Col1A1, Tenascin-c, PAI-1 and MMP-1 gene expression after MP treatment.

Conclusions: MP conserve some of the properties attributed to the living MSC. This study shows that MP target lung cells, via which they may have a broad anti-fibrotic effect.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • A549 Cells
  • Adult
  • Aged
  • Cell-Derived Microparticles / transplantation*
  • Coculture Techniques
  • Female
  • Fibroblasts
  • Gene Expression Regulation
  • Humans
  • Idiopathic Pulmonary Fibrosis / pathology
  • Idiopathic Pulmonary Fibrosis / therapy*
  • Lung / cytology
  • Lung / pathology
  • Male
  • Mesenchymal Stem Cell Transplantation / adverse effects
  • Mesenchymal Stem Cells / cytology*
  • Middle Aged
  • Nanoparticles / therapeutic use*
  • Primary Cell Culture / methods*
  • Subcutaneous Fat / cytology
  • Telomere Shortening

Grants and funding

This collaboration project is co-funded by the PPP Allowance made available by Health Holland, Top Sector Life Sciences & Health, of the Dutch Ministry of Economic affairs to stimulate public-private partnerships, and by the Institute of Health Carlos III (ISCIII, PI18/00367), co-funded by FEDER funds/European Regional Development Fund (ERDF) – “a Way to Build Europe” and Biomedical National Research Network CIBER.